Prostate Cancer Patient Management Simulator
Optimal prostate cancer treatment requires appropriate stratification of patients into risk groups that inform the best guideline-recommended approaches. Tumor-based molecular testing and emerging refinement of risk group criteria hold promise to improve the risk stratification process. Furthermore, recent data have the potential to impact the ways in which ADT is used across several settings of prostate cancer. Guidelines and data also inform the sequencing of treatment options for castration-recurrent/resistant prostate cancer and metastatic disease. Knowledge about the guidelines and recent clinical advances allows for informed, shared decision making, which can enable patients to receive optimal care that maximizes their survival while considering their values and preferences.
The goal of this project is to ensure that physicians, nurses, and other relevant healthcare professionals have the knowledge and skills necessary to apply the standards of care to their practice and healthcare setting for patients with prostate cancer. This activity will help reach that goal through the provision of up-to-date information and broadening clinician confidence in applying new evidence to practice.
This learning platform is designed to meet the educational needs of multidisciplinary specialties that manage the treatment of prostate cancer including medical and radiation oncologists, urologists, pathologists, oncology nurses, mid-level practitioners, and fellows.
Following this activity, participants should be able to:
- Describe the potential risks and benefits of molecular testing in prostate cancer risk stratification.
- Discuss how the intermediate-risk groups can be further refined into favorable and unfavorable subgroups.
- Explain recent data impacting the ways in which ADT is used in castration-naïve prostate cancer.
- Explain considerations for the selection of appropriate sequences of treatments for patients with castration-recurrent/resistant prostate cancer.
James Mohler, MD – Dr. Mohler is Associate Director and Senior Vice President for Translational Research, Chief, Inter-Institutional Academics, and Professor of Oncology, at Roswell Park Cancer Institute; Professor of Urology at the University at Buffalo School of Medicine and Biomedical Sciences; and Adjunct Professor of Urology and Member of UNC-Lineberger Comprehensive Cancer Center at University of North Carolina.
Richard J. Lee, MD, PhD – Dr. Lee is Assistant Professor of Medicine at Massachusetts General Hospital and Assistant Professor of Medicine at Harvard Medical School.
Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education (CE) activities are expected to disclose any relevant financial relationships with a commercial interest as defined by ACCME’s, ACPE’s and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.
NCCN continuing education considers financial relationships to create a “conflict of interest” when an individual has both a financial relationship with a commercial interest and the opportunity to affect CE content about the products or services of a commercial interest with which he/she and/or a spouse or partner has a financial relationship.
NCCN continuing education considers “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest. NCCN does not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling.
The faculty listed below discloses no relevant financial relationships:
James Mohler, MD
The faculty listed below discloses the following relevant financial relationships:
Richard J. Lee, MD, PhD
AstraZeneca Pharmaceuticals LP: Scientific Advisor
Bayer HealthCare: Scientific Advisor
Genentech, Inc.: Scientific Advisor
Janssen Pharmaceutica Products, LP: Scientific Advisor
The Activity Planning staff listed below discloses no relevant financial relationships:
NCCN: Kimberly Bayer; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Karen Kanefield; Rashmi Kumar, PhD; Joan S. McClure, MS; Melinda Somasekhar, PhD (employed by NCCN until 10/30/2017); Melanie Moletzsky; Lisa Perfidio, MS; Kathy Ann Smith, CMP, CHCP
Syandus, Inc: Allyson Lehrman, DPM; Douglas Seifert, PhD
The NCCN Clinical staff listed below discloses no relevant financial relationships:
Deborah Freedman-Cass, PhD
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of National Comprehensive Cancer Network (NCCN) and Syandus, Inc. NCCN is accredited by the ACCME to provide continuing medical education for physicians.
NCCN designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Aggregated participant data will be shared with the commercial supporters of this activity.
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 2.0 hours of Category 1 credit for completing this activity.
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
NCCN designates this educational activity for a maximum of 2.0 contact hours.
Method of Participation to Earn Credit
- Read the target audience, learning objectives, and faculty disclosures.
- Launch the simulation by clicking the Take Course button. (Please note that you will be directed to another site for the simulation.) Interact appropriately to satisfy each objective to unlock the next objective. The simulation will track your progress until all objectives and assessment components are complete. If you exit, the simulation will save your progress so that you can return to finish at a later time.
- As you successfully complete more scenarios, you will qualify for increasing levels of CE credit (ranging from 0.5 to 2.0 credits). Click or tap “Credit” to determine your CE credit status and receive credit. Upon successful completion of the post-test and evaluation, you will receive a certificate of credit immediately via email (if connected to the internet). If you wish to complete more of the simulation and receive more CE credit, simply request additional credit.